Michal Sarnecki, MD

Medical Leader VX Bern Clin
Janssen Research & Development, Janssen Vaccines, Switzerland

Disclosure(s): Janssen: Employee, Stocks/Bonds

Michal Sarnecki, MD, is Director of Clinical Development at Janssen Research & Development in the department of Infectious Diseases & Vaccines and is based in Bern, Switzerland. He is currently the Medical Lead of the Janssen investigational vaccine for the prevention of invasive infections due to extraintestinal pathogenic Escherichia coli.

Poster(s):

• 120 - Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 235 - Tracking Invasive Extraintestinal Pathogenic Escherichia coli Disease in Older Adults in a Community-Based Clinical Trial Setting
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1823 - Clinical Profile and Antimicrobial Susceptibility of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Hospitalized Adults Aged ≥60 Years
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET